Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Overview

Journal Diabetes Ther

Specialty Cardiology & Vascular Diseases

Date 2021 Feb 24

PMID 33625721

Citations 5

Authors

Qiu Wang

Lirong Ma

Yuanying Zhang

Lin Zhang

Yu An

Jia Liu

Guang Wang

Affiliations

Soon will be listed here.

Abstract

Introduction: Irisin is a unique myokine with striking effects on regulating insulin sensitivity and energy metabolism. This study aimed to investigate the changes in serum irisin in patients with newly diagnosed type 2 diabetes mellitus (T2DM) following sitagliptin treatment.

Methods: Thirty-two patients with T2DM were treated with 100 mg/day sitagliptin for 16 weeks. Twenty age-, sex- and body mass index (BMI)-matched healthy subjects were enrolled as the control group. Irisin and metabolic parameters were measured at baseline and after treatment.

Results: Patients with T2DM had lower irisin levels than the controls (10.03 ± 2.06 vs. 13.06 ± 3.10 ng/ml, P < 0.01). Sitagliptin treatment significantly increased serum irisin levels in T2DM patients compared to baseline (11.18 ± 1.91 vs. 10.03 ± 2.06 ng/ml, P < 0.01). Increased irisin levels were associated with decreased fasting blood glucose (FBG) (β = - 0.24, P < 0.05) and glycosylated hemoglobin (HbA1c) (β = - 0.15, P < 0.05).

Conclusions: Sitagliptin treatment significantly increased serum irisin levels in patients with T2DM, and the increase of the irisin level was associated with decreases of FBG and HbA1c levels. These results suggest that irisin might be involved in the antidiabetic mechanisms of sitagliptin.

Trial Registration: ClinicalTrials.gov identifier NCT04495881.

Citing Articles

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers.

Rentflejsz J, Wojszel Z J Clin Med. 2024; 13(4).

PMID: 38398421 PMC: 10889814. DOI: 10.3390/jcm13041107.

Move Your Body toward Healthy Aging: Potential Neuroprotective Mechanisms of Irisin in Alzheimer's Disease.

Bellettini-Santos T, Batista-Silva H, Marcolongo-Pereira C, Quintela-Castro F, Barcelos R, Chiepe K Int J Mol Sci. 2023; 24(15).

PMID: 37569815 PMC: 10420140. DOI: 10.3390/ijms241512440.

Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes.

Wang Q, An Y, Zhang L, Zhang Y, Wang G, Liu J BMC Endocr Disord. 2022; 22(1):306.

PMID: 36476135 PMC: 9727947. DOI: 10.1186/s12902-022-01233-x.

Sitagliptin Attenuates the Cognitive Deficits in L-Methionine-Induced Vascular Dementia in Rats.

Khodir S, Faried M, Abd-Elhafiz H, Sweed E Biomed Res Int. 2022; 2022:7222590.

PMID: 35265716 PMC: 8898801. DOI: 10.1155/2022/7222590.

Glucosamine Ameliorates Symptoms of High-Fat Diet-Fed Mice by Reversing Imbalanced Gut Microbiota.

Yuan X, Zheng J, Ren L, Jiao S, Feng C, Du Y Front Pharmacol. 2021; 12:694107.

PMID: 34149435 PMC: 8209492. DOI: 10.3389/fphar.2021.694107.

References

Liu Y, Xu F, Jiang P . Effect of sitagliptin on expression of skeletal muscle peroxisome proliferator-activated receptor coactivator-1 and irisin in a rat model of type 2 diabetes mellitus. J Int Med Res. 2020; 48(5):300060519885569. PMC: 7218978. DOI: 10.1177/0300060519885569. View

Yuksel M, Oncul M, Tuten A, Imamoglu M, Acikgoz A, Kucur M . Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus. Diabetes Res Clin Pract. 2014; 104(1):171-5. DOI: 10.1016/j.diabres.2013.12.025. View

Kulkarni R, Bruning J, Winnay J, Postic C, Magnuson M, Kahn C . Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell. 1999; 96(3):329-39. DOI: 10.1016/s0092-8674(00)80546-2. View

Liu J, Wong M, Toy W, Tan C, Liu S, Ng X . Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013; 27(4):365-9. DOI: 10.1016/j.jdiacomp.2013.03.002. View

Huh J, Mougios V, Kabasakalis A, Fatouros I, Siopi A, Douroudos I . Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocrinol Metab. 2014; 99(11):E2154-61. DOI: 10.1210/jc.2014-1437. View

Moreno-Navarrete J, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F . Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013; 98(4):E769-78. DOI: 10.1210/jc.2012-2749. View

Polyzos S, Kountouras J, Anastasilakis A, Geladari E, Mantzoros C . Irisin in patients with nonalcoholic fatty liver disease. Metabolism. 2013; 63(2):207-17. DOI: 10.1016/j.metabol.2013.09.013. View

Herman W, Dungan K, Wolffenbuttel B, Buse J, Fahrbach J, Jiang H . Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009; 94(5):1689-94. DOI: 10.1210/jc.2008-1940. View

Sanchis-Gomar F, Perez-Quilis C . The p38-PGC-1α-irisin-betatrophin axis: Exploring new pathways in insulin resistance. Adipocyte. 2014; 3(1):67-8. PMC: 3917937. DOI: 10.4161/adip.27370. View

10.

Shirakawa J, Amo K, Ohminami H, Orime K, Togashi Y, Ito Y . Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. J Biol Chem. 2011; 286(29):25467-76. PMC: 3138313. DOI: 10.1074/jbc.M110.217216. View

11.

Chang C, Huang S, Soong Y, Cheng P, Wang C, Liang I . Circulating irisin and glucose-dependent insulinotropic peptide are associated with the development of polycystic ovary syndrome. J Clin Endocrinol Metab. 2014; 99(12):E2539-48. DOI: 10.1210/jc.2014-1180. View

12.

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

13.

de la Iglesia R, Lopez-Legarrea P, Crujeiras A, Pardo M, Casanueva F, Zulet M . Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients. Clin Endocrinol (Oxf). 2013; 81(2):306-11. DOI: 10.1111/cen.12383. View

14.

Scott R, Loeys T, Davies M, Engel S . Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008; 10(10):959-69. DOI: 10.1111/j.1463-1326.2007.00839.x. View

15.

Bostrom P, Wu J, Jedrychowski M, Korde A, Ye L, Lo J . A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481(7382):463-8. PMC: 3522098. DOI: 10.1038/nature10777. View

16.

Takihata M, Nakamura A, Tajima K, Inazumi T, Komatsu Y, Tamura H . Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes Obes Metab. 2013; 15(5):455-62. DOI: 10.1111/dom.12055. View

17.

Park K, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung K . Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013; 98(12):4899-907. PMC: 3849667. DOI: 10.1210/jc.2013-2373. View

18.

Duan H, Ma B, Ma X, Wang H, Ni Z, Wang B . Anti-diabetic activity of recombinant irisin in STZ-induced insulin-deficient diabetic mice. Int J Biol Macromol. 2015; 84:457-63. DOI: 10.1016/j.ijbiomac.2015.12.049. View

19.

Lee H, Lee J, Kim N, Kim J, Kim H, Lee Y . Irisin, a Novel Myokine, Regulates Glucose Uptake in Skeletal Muscle Cells via AMPK. Mol Endocrinol. 2015; 29(6):873-81. PMC: 5414737. DOI: 10.1210/me.2014-1353. View

20.

Huh J, Siopi A, Mougios V, Park K, Mantzoros C . Irisin in response to exercise in humans with and without metabolic syndrome. J Clin Endocrinol Metab. 2014; 100(3):E453-7. DOI: 10.1210/jc.2014-2416. View